About Us
Jiuzhitang Maker
Development History
2025
Jiuzhitang Maker has established a wholly-owned subsidiary in Guangzhou's Nansha District—Jiuzhitang Maker (Guangzhou) Cell Technology Co., Ltd.
10-28
Jiuzhitang Maker's clinical trial for stem cell therapy targeting autism spectrum disorder officially kicks off.
08-26
The third new drug clinical trial application (IND) of Jiuzhitang Meike has been granted implied permission by the National Medical Products Administration (acceptance number: CXSL2400859), with indications for autism spectrum disorder (ASD)
03-11
2024
10-17
Jiuzhitang Maker Wins Top Prize at Tsinghua Alumni Global Finals for Health and Medical Innovation
03-29
Jiuzhitang Maker's Quality Control Department has been awarded the accreditation certificate by the China National Accreditation Service for Conformity Assessment (CNAS).
2023
Jiuzhitang Maker named to Huayi List's "Top 10 Most Promising Stem Cell Companies" list
12-08
Jiuzhitang Maker's Phase II clinical trial for stem cell therapy targeting autoimmune alveolar proteinosis (aPAP) officially kicks off.
11-01
The second new drug clinical trial application (IND) has been granted implied permission by the National Medical Products Administration (acceptance number: CXSL2300202), with indications for autoimmune pulmonary alveolar proteinosis (aPAP)
06-09
Jiuzhitang Maker-Founded Key Laboratory in Hunan Province Approved
06-07
Jiuzhitang Maker Obtained the "Certificate of Quality Management for Stem Cell Preparation" issued by the China Medical Biotechnology Association.The fifth stem cell preparation company certified by the China Medical Biotechnology Association
03-10
Jiuzhitang Maker has achieved ISO9001, ISO14001, and ISO45001 international standard certifications.
02-07
2022
10-26
Jiuzhitang Maker's four bone marrow mesenchymal stem cell products, derived from different donors, have passed comprehensive testing by the National Institute for Control of Pharmaceutical and Biological Products and met all required standards.
09-01
Jiuzhitang Maker Named to Beijing's "Specialized, Fine, and New" Enterprise List
01-07
Jiuzhitang Maker wins two major awards at the "2021 Brand Powerhouse Economic Forum (5th Edition)"
2021
Jiuzhitang Maker Receives District-Level Enterprise R&D Institution License
12-22
The "Ethical Assessment Guidelines for Stem Cell Sources," co-drafted by Jiuzhitang Maker, has been officially released.
11-25
Jiuzhitang Maker wins the "2021 China Biopharmaceutical Company with Growth Potential Award"
10-11
Jiuzhitang Maker Receives Funding Support for the Daxing District Project Promoting the Transfer and Commercialization of Scientific and Technological Achievements
02-25
China's first clinical trial using imported stem cells to treat ischemic stroke has officially launched.
01-12
2020
12-19
Jiuzhitang Maker awarded the "2020 Outstanding Corporate Social Responsibility Enterprise" prize by Health News.
12-18
The Jiuzhitang Maker Postdoctoral Research Workstation Sub-station Officially Awarded a Plaque
11-02
Jiuzhitang Maker named among the "Top 50 Most Innovative Biopharmaceutical Companies in China 2020"
07-06
Jiuzhitang Maker Signs Clinical Trial Agreement with TianTan Hospital
04-02
Jiuzhitang Maker Receives Funding Support from Daxing District to Boost the Development of the Pharmaceutical and Healthcare Industry
03-20
Jiuzhitang Maker Selected for Government's "COVID-19 Prevention and Control" Technology Transfer Project
02-19
Jiuzhitang Maker's stem-cell-based new drug clinical trial receives approval.
01-14
Jiuzhitang Maker awarded the title of "Zhongguancun Golden Seed Enterprise"
2019
Jiuzhitang Maker Receives Major Science and Technology Project Funding from Beijing Municipality
12-24
Jiuzhitang Maker's Daxing production base has been fully completed, and all employees have moved in.
12-18
Jiuzhitang Maker's clinical trial application for its stem-cell-based new drug has been accepted by the National Center for Drug Evaluation.
11-21
Jiuzhitang Maker's application for R&D funding as a "2019 Zhongguancun Demonstration Zone Science and Technology Small and Micro Enterprise" has been successfully approved.
10-24
Jiuzhitang Maker officially receives the "National High-Tech Enterprise" certificate.
10-22
Jiuzhitang Maker has officially joined the Chinese Society for Cell Biology as a corporate member.
05-30
Jiuzhitang Maker's the construction project located in Daxing Zhongguancun Medical Equipment Park has obtained the park construction permit and issued the construction certificate. The decoration of Meike Daxing production base has officially started
03-22
Jiuzhitang Maker officially receives the "Zhongguancun High-Tech Enterprise" certificate.
02-25
2018
11-09
Jiuzhitang Maker signs a "Joint Construction Agreement for a Clinical Stem Cell Research Base" with Beijing Tiantan Hospital, Affiliated to Capital Medical University.
03-13
Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. Established
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy
Business license